The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% clinical benefit rate in recurrent LGSOC. Researchers explore a promising ...

Breast cancer is the most common cancer in women in almost all countries around the world. Around three-quarters of breast cancers are ER-positive, meaning that the tumors have many estrogen receptors ...

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in the brain during Alzheimer's, potentially slowing or even ...

Women now have another drug they can take to prevent breast cancer from returning after surgery to remove the tumor. The federal Food and Drug Administration on Wednesday approved a new use for Femara ...